title: Efficacy, toxicity and feasibility of a shorter schedule of DCEP regimen for stem cell mobilization in multiple myeloma.
abstract: From 2000 to 2004, 152 patients with multiple myeloma aged <or=65 years, enrolled in high-dose programs, were treated with two schedules of DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin): 106 patients (group I) were mobilized with the infusional version of DCEP (infusional-DCEP), and 46 patients (group II) with a shorter version (DCEP-short). The median number of CD34(+) cells collected was similar in the two groups as was the percentage of patients yielding >or=4 x 10(6) cells/kg. The proportion of patients in whom mobilization failed was similar in the two groups. The incidence of WHO grade III neutropenia was higher in group II, although the difference was not statistically significant; the percentage of patients requiring hospitalization for severe infections was similar in the two groups. The incidence of WHO grade IV thrombocytopenia did not differ between the two groups. The response rate was 72% in group I and 80% in group II with similar percentages of patients achieving good responses. DCEP-short is a good mobilizing regimen, sharing the same characteristics as infusional-DCEP: high mobilizing efficacy, low toxicity and good antitumor activity. This new schedule of DCEP does, however, allow complete outpatient management and so could be advantageously included in any high-dose therapy program.
authors.affiliation: Division of Hematology, Istituto Scientifico Policlinico San Matteo, University of Pavia, Italy. a.corso@smatteo.pv.it
authors.forename: A
authors.initials: A
authors.lastname: Corso
authors.forename: S
authors.initials: S
authors.lastname: Mangiacavalli
authors.forename: A
authors.initials: A
authors.lastname: Nosari
authors.forename: C
authors.initials: C
authors.lastname: Castagnola
authors.forename: P
authors.initials: P
authors.lastname: Zappasodi
authors.forename: A M
authors.initials: AM
authors.lastname: Cafro
authors.forename: C
authors.initials: C
authors.lastname: Astori
authors.forename: M
authors.initials: M
authors.lastname: Bonfichi
authors.forename: M
authors.initials: M
authors.lastname: Varettoni
authors.forename: C
authors.initials: C
authors.lastname: Rusconi
authors.forename: D
authors.initials: D
authors.lastname: Troletti
authors.forename: C
authors.initials: C
authors.lastname: Pascutto
authors.forename: E
authors.initials: E
authors.lastname: Morra
authors.forename: M
authors.initials: M
authors.lastname: Lazzarino
mesh_terms: D018952:Antigens, CD34 / Q000032:analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000633:toxicity; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D005240:Feasibility Studies; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D006801:Humans; D007239:Infections / Q000139:chemically induced; D009101:Multiple Myeloma / Q000150:complications / Q000628:therapy*; D009503:Neutropenia / Q000139:chemically induced; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods; D012189:Retrospective Studies; D013921:Thrombocytopenia / Q000139:chemically induced
chemical_list: D018952:Antigens, CD34; D005047:Etoposide; D003907:Dexamethasone; D003520:Cyclophosphamide; D002945:Cisplatin